Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Not yet recruiting2
unknown1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

not_yet_recruiting240%
unknown120%
recruiting120%
active_not_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_1

CAN1012 in Pre-malignant Oral Dysplasia

NCT07620496
not_yet_recruitingphase_1

CAN1012 in Pre-Malignant DCIS and LCIS

NCT07408856
active_not_recruitingphase_1

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

NCT05580991
recruitingphase_1

CAN1012 Combined With PD-1 in Patients With Solid Tumors

NCT06410703
unknownphase_1

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

NCT04987112

Clinical Trials (5)

Showing 5 of 5 trials
NCT07620496Phase 1

CAN1012 in Pre-malignant Oral Dysplasia

Not Yet Recruiting
NCT07408856Phase 1

CAN1012 in Pre-Malignant DCIS and LCIS

Not Yet Recruiting
NCT05580991Phase 1

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Active Not Recruiting
NCT06410703Phase 1

CAN1012 Combined With PD-1 in Patients With Solid Tumors

Recruiting
NCT04987112Phase 1

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5